Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor

The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios. A deeper knowledge o...

Descripción completa

Detalles Bibliográficos
Autores principales: Mollica, Veronica, Di Nunno, Vincenzo, Gatto, Lidia, Santoni, Matteo, Scarpelli, Marina, Cimadamore, Alessia, Lopez-Beltran, Antonio, Cheng, Liang, Battelli, Nicola, Montironi, Rodolfo, Massari, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627706/
https://www.ncbi.nlm.nih.gov/pubmed/31207938
http://dx.doi.org/10.3390/cancers11060830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627706/
https://www.ncbi.nlm.nih.gov/pubmed/31207938
http://dx.doi.org/10.3390/cancers11060830

Ejemplares similares